Search Results - "Collon, Thierry"

Major changes in lung cancer over the last ten years in France: The KBP-CPHG studies by Locher, Chrystèle, Debieuvre, Didier, Coëtmeur, Daniel, Goupil, François, Molinier, Olivier, Collon, Thierry, Dayen, Charles, Le Treut, Jacques, Asselain, Bernard, Martin, Francis, Blanchon, François, Grivaux, Michel

“…Abstract The incidence of lung cancer has dramatically increased in ten years, being now the most commonly diagnosed cancer in males and the fourth most…”
Get full text

Improved survival on morning pembrolizumab with or without chemotherapy during initial treatment for stage IV non-small cell lung cancer by Karaboué, Abdoulaye, Collon, Thierry, Innominato, Pasquale, Chouahnia, Kader, Adam, René, Levi, Francis

“…e21055 Background: Seven retrospective studies have shown that a greater proportion of infusions of immune checkpoint inhibitors (ICIs) in the morning or at…”
Get full text

Circadian variation in nivolumab efficacy in patients with advanced non-small cell lung cancer by Karaboué, Abdoulaye, Bisseux, Laurence, Pavese, Ida, Collon, Thierry

“…Abstract only e21585 Background: Despite efficacy of human checkpoint inhibitors, only 20 to 30% of treated patients present long term benefits. Circadian…”
Get full text

Nivolumab timing as a major survival predictor in patients with stage IV non–small cell lung cancer by Karaboué, Abdoulaye, Collon, Thierry, Bodiguel, Viviane, Cucherousset, Joel, Innominato, Pasquale, Bouchahda, Mohamed, Adam, Rene, Levi, Francis

“…9058 Background: Functional activity and trafficking of T(CD8) and other immune cells are regulated over the 24 hours by the circadian timing system. Nivolumab…”
Get full text

Time-dependent efficacy of checkpoint inhibitor nivolumab in metastatic lung cancer patients by Karaboué, Abdoulaye, Collon, Thierry, Pavese, Ida, Bodiguel, Viviane, Zakine, Elda, Innominato, Pasquale, Bouchahda, Mohamed, Adam, René, Levi, Francis

“…Abstract only 9096 Background: Nivolumab (NIV) is a Programmed-cell-Death-1 inhibitor approved as 2nd line treatment for metastatic Non-Small Cell Lung Cancer…”
Get full text

Time-Dependent Efficacy of Checkpoint Inhibitor Nivolumab: Results from a Pilot Study in Patients with Metastatic Non-Small-Cell Lung Cancer by Karaboué, Abdoulaye, Collon, Thierry, Pavese, Ida, Bodiguel, Viviane, Cucherousset, Joel, Zakine, Elda, Innominato, Pasquale F, Bouchahda, Mohamed, Adam, René, Lévi, Francis

“…Prior experimental and human studies have demonstrated the circadian organization of immune cells' proliferation, trafficking, and antigen recognition and…”
Get full text

Impact on treatment adherence, side effects control, patients QoL, and rehospitalization rate through new management of oral chemotherapy by Pavese, Ida, Collon, Thierry, Chait, Yasmine, Cherait, Amine, Bisseux, Laurence, MBarek, Besma, Miette, Carole, Imbeau, Jocelyne, Iurisci, Ida

“…Abstract only…”
Get full text

Polyarthralgia-arthritis syndrome induced by low doses of rifabutin by Le Gars, L, Collon, T, Picard, O, Kaplan, G, Berenbaum, F

“…We describe 2 cases of polyarthralgia-arthritis syndrome induced by rifabutin, an effective treatment for infections of Mycobacterium avium intracellulare…”
Get more information